our work: case study

Case-based Learning Program
Case-based Learning Program

Case-based Learning Program

Targeted to hematologists, nurses, pharmacists and GPs, the Leadership in Lymphoma case-based learning program is an accredited continuing medical education initiative exploring treatment modalities and best practices in non-Hodgkin’s lymphoma (NHL). During the program, the most current clinical information is presented and a case reviewed that demonstrates the application of the information to practice. Remedy partnered with leading hematologists and Queen’s University in the development and accreditation of course materials.

The Big Picture

The program has been designed to engage different learning styles and needs. When used in a small-group learning session, the material is presented by a clinical expert in NHL. Understanding of the topic is strengthened by means of group discussion and a question-and-answer period. Each program is tailored to meet the interests and learning needs of attendees. As an on-line format, the participant has the benefit of working through the program at their convenience. To enhance the key messages and in-class feel of the program, the participant watches a video of the case presented by the case developer. Key questions are posed along the way and the participant can pause the video to reflect upon his or her response. Both the on-line and off-line approaches receive the same number of credits.

Digging Deeper

The three patient scenarios represent actual cases that were managed by the case developers. To provide additional insights and materials for the program, a second team of hematologists was asked to review and to endorse all the materials.

In Practice

The program has been positively received in both Canada and Europe. In Canada, it has been used as a preparation course for medical residents and a training tool for nurses.

Global representatives have shared the program with one of the European teams who have expressed an interest in rolling out a similar program to their medical community.